Results for tag: "Anti Vascular Endothelial Growth Factor Therapeutics"

Anti-vascular endothelial growth factor (anti-VEGF) therapeutics have emerged within the field of cardiovascular drugs as targeted treatments primarily for conditions characterized by abnormal angiogenesis—the growth of new blood vessels. While anti-VEGF drugs were initially developed to counteract cancerous tumor growth, which often relies on angiogenesis for nutrient supply, their application in cardiovascular diseases also addresses conditions such as diabetic retinopathy and age-related macular degeneration, where excessive vascular proliferation can lead to vision loss. Cardiovascular diseases where VEGF plays a role include those where ischemia triggers pathological angiogenesis, although this remains a developing area of research and therapy. These medications function by inhibiting the VEGF pathway, thereby reducing the proliferation and permeability of endothelial cells that form the lining of blood vessels. Anti-VEGF therapeutics may be administered through various methods, including intravitreal injections, for conditions affecting the eye or systemically for broader impact. While these treatments offer novel mechanisms of action compared to traditional cardiovascular drugs such as statins and anticoagulants, they represent a specialized and evolving component of the therapeutic landscape, addressing a distinct subset of cardiovascular-related conditions. Companies active in the anti-VEGF therapeutics market include Regeneron Pharmaceuticals, which manufactures aflibercept, and Roche's Genentech, which produces ranibizumab and bevacizumab. Other players consist of Bayer AG and Novartis, all contributing to research, Show Less Read more